OREXO AB Positive EBITDA in H2 setting the target for FY 2024
Q4 2023 highlights
› Total net revenues of
› EBITDA of
› Net earnings of
› US Pharma segment (Zubsolv® US) net revenues of
› Cash flow from operating activities of
› Earnings per share before and after dilution amounted to
› The MODIA® study didn't meet the primary end-points, but showed high rates of treatment response in both study arms, with no adverse events associated with the use of MODIA
›
› FDA accepted the New Drug Application filing for review of OX124, a high-dose rescue medication for opioid overdose with naloxone
› Financial outlook provided for 2024 on page 15.
Important events after the end of the period
› MODIA and Vorvida® will be reimbursed within the US Veterans Affairs Federal Supply Schedule as of January 1, 2024.
| SEK m unless otherwise stated | 2023 Oct-Dec | 2022 Oct-Dec | 2023 Jan-Dec | 2022 Jan-Dec |
| Net revenues | 166.0 | 156.1 | 638.8 | 624.3 |
| Cost of goods sold | -20.1 | -25.9 | -88.9 | -102.6 |
| Operating expenses | -154.5 | -201.3 | -659.5 | -705.6 |
| EBIT | -8.6 | -71.1 | -109.5 | -183.9 |
| EBIT margin | -5.2% | -45.6% | -17.1% | -29.5% |
| EBITDA | 12.4 | -53.1 | -32.5 | -115.2 |
| Earnings per share. before dilution. SEK | -0.54 | -2.67 | -3.73 | -5.17 |
| Earnings per share. after dilution. SEK | -0.54 | -2.67 | -3.73 | -5.17 |
| Cash flow from operating activities | -2.6 | -48.9 | -95.0 | -156.6 |
| Cash and invested funds | 171.0 | 351.9 | 171.0 | 351.9 |
Financial outlook 2024
** The buprenorphine/naloxone market will grow 2-5 percent, based on current growth trajectory
** Zubsolv net sales in USD will be in line with 2023
** Cost control is a priority and OPEX excluding depreciation and amortization will decline from
below
** Positive EBITDA for the FY 2024.
The financial outlook 2024 is based on a forward looking assumption of a USD/SEK exchange rate of 10.28 calculated
as an average of
Strong recovery in financial results and FDA initiated the review of OX124
CEO Comments in brief
I am pleased to report a Q4 result delivering a positive EBITDA and strong Zubsolv® net sales both compared to Q4 2022 and Q3 2023. Zubsolv net sales year over year grew more than 6 percent in both SEK and USD, and nearly 8 percent quarter over quarter. I am also delighted to share that we are continuing to drive efficiencies across the business and have reduced operating expenses by 23 percent from last year. This recovery in financial performance is not driven by exchange rates, on the contrary, our EBITDA in H2 would have been nearly
I am also pleased to announce that we, despite currency headwinds, reached our financial guidance for 2023, and in particular the positive EBITDA for H2. With relatively stable exchange rates and no other extraordinary events in 2024, we are confident we can reach a positive EBITDA for the FY 2024.
To read the full CEO Comments view attached PDF.
Contact persons quarterly report
Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: ir@orexo.com.
Presentation
On
To attend via teleconference where you can ask questions verbally:
https://conference.financialhearings.com/teleconference/?id=2001504
When registered you will be provided phone numbers and a conference ID to access the conference.
To attend via webcast:
https://ir.financialhearings.com/orexo-q4-2023
Prior to the call, presentation material will be available on the website under Investors/Reports/Audiocasts.
This information is information that
https://news.cision.com/orexo/r/orexo-interim-report-q4-2023--incl--full-year-report,c3924484
https://mb.cision.com/Main/694/3924484/2589855.pdf
(c) 2024 Cision. All rights reserved., source
